Drug intelligence / Profile preview

InR target 2

Development stage: Preclinical
Lead developer: 149 Bio

Overview

**InR target 2** is a preclinical-stage therapeutic candidate being developed by **149 Bio** (also known as **Allosite Tx**). The program is currently focused on undisclosed indications within the field of **immunology and inflammation (I&I)**. As of early 2026, specific details regarding the molecular target, modality, and mechanism of action remain proprietary and have not been publicly disclosed. The developer, 149 Bio, utilizes a platform focused on the discovery of allosteric modulators for complex protein targets, suggesting the asset may function through an allosteric mechanism.

Beyond the preview

Go deeper on InR target 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InR target 2.

Explore the full profile